Related Experiment Video
Updated: Oct 1, 2025
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.5K
SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibition
Xi Su1, Dong Chen1, Lizhang Zhu1
1Department of Thyroid and Parathyroid Surgery, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Centre, Shenzhen, Guangdong Province, China.
Cell Death & Disease
|March 10, 2022
Summary
Small G protein signaling modulators 2 (SGSM2) acts as a tumor suppressor in thyroid cancer (TC). Lower SGSM2 levels correlate with poor prognosis, and its activation inhibits TC cell growth and metastasis by regulating RAP1/RAS signaling.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Thyroid cancer (TC) is a growing global health concern.
- Small G protein signaling modulators 2 (SGSM2) is implicated in various cancers, but its role in TC is unelucidated.
Purpose of the Study:
- To investigate the function and molecular mechanism of SGSM2 in thyroid tumorigenesis.
- To determine SGSM2's potential as a therapeutic target in specific TC subtypes.
Main Methods:
- Analysis of SGSM2 expression in TC tissues and correlation with patient prognosis.
- Functional assays (proliferation, migration, invasion) of TC cells with altered SGSM2 levels.
- Investigation of SGSM2's interaction with signaling proteins like RAP1 and RAS.
Main Results:
- SGSM2 expression is significantly reduced in TC, associated with poorer patient outcomes.
- Ectopic SGSM2 expression suppresses proliferation, migration, invasion, and tumorigenicity in wild-type RAS TC cells.
- SGSM2 interacts with RAP1, enhancing its activity to competitively inhibit RAS activation and downstream MAPK/ERK and PI3K/Akt signaling.
Conclusions:
- SGSM2 functions as a tumor suppressor in thyroid cancer.
- SGSM2 exerts its tumor-suppressive effects by modulating the RAP1/RAS/MAPK/ERK/PI3K/Akt pathways.
- SGSM2 represents a potential therapeutic target for thyroid cancers with wild-type RAS.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.1K
02:38The Ras Gene
6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.5K
01:24Small GTPases - Ras and Rho
4.3K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.3K
01:16TGF - β Signaling Pathway
7.9K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.9K
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K